May 28, 2012
The Obama administration recently announced that the US government will assist pharmaceutical corporations in finding prescription drugs to treat new diseases.
The focus of this collaboration will identify new uses for drugs that have already been approved by the Food and Drug Administration (FDA).
“We need to speed the pace at which we are turning discoveries into better health outcomes,” said Dr. Francis Collins, of the National Institutes of Health (NIH). “NIH looks forward to working with our partners in industry and academia to tackle an urgent need that is beyond the scope of any one organization or sector.”
Obama signed Executive Order (EO), Establishing the National Prevention, Health Promotion and Public Health Council in 2010.
Now the medical journal Cell has published a research paper on using an extremely dangerous psychotropic pharmaceutical to treat cancer; one that has traditionally been used to treat schizophrenia.
Thioridazine is expected to be used to select and eradicate cancer stem cells that are found in leukemia and several other cancers such as breast, blood, brain, prostate, ovarian, lung and gastrointestinal.
Scientists claim that this hazardous pharmaceutical can be administered in cancer therapies, without the health-threatening side effects of current drugs on the market. It is being advertised as an alternative to chemotherapy and radiation.
A robotic stem cell screening system was devised by the research team to siphon through large amounts of drugs and previously unpublished data and drugs that are available on the market today. Thousands of chemical compounds were screened for potential effects on specifically breast cancer and leukemia.
“We discovered the drug by creating a new way of looking at different chemicals,” said Mick Bhatia, the principal investigator for the study and scientific director of McMaster’s Stem Cell and Cancer Research Institute in the Michael G. DeGroote School of Medicine.
In order to do that, we have to put cancer stem cells in a dish, but also have normal stem cells to also test the compounds. We were able to do this with a robotic system, fully automated, that allowed us to go through 10 or 15 compounds [at first]. Now we can do this with thousands of compounds, eventually arriving at this drug that doesn’t do anything to normal stem cells, but kills cancer stem cells.
The unusual aspect of our finding is the way this human-ready drug actually kills cancer stem cells; by changing them into cells that are non-cancerous.
The praise Thioridazine is receiving omits the dangerous effects that this drug causes in humans.
- Urinary tract infections
- Slowed movements
- Inability to produce facial expressions
- Parkinson’s disease
- Irregular heart beat
- Sudden death
Thioridazine is classified as a conventional antipsychotic. Its prime function is to reduce the brain’s ability to process excitement; effectively rendering the patient docile and even-tempered.
There is a strong possibility of committing suicide while on this drug.
Bhatia’s study asserts that this discovery could inspire a new frontier in cancer therapies. He stated that there are an estimated 12 existing drugs that pose a “good potential for the same response.”
The researchers are not stopping with Thioridazine; they are moving onto other possible uses for already approved drugs.
Bhatia’s team is anxious to begin human trials with plans to use this pharmaceutical on leukemia patients. By studying patients whose cancer is in remission, the researchers hope to find that thioridazine will prevent a multitude of cancers.
Currently, the vitamin industries, by order of the Codex Alimentarius (CA) are being attacked by the US government to justify the force outlawing of natural medicine use. The CA is a creation of the World Health Organization (WHO) and the Food and Agriculture Organization of the United Nations.
The findings of this study are just the first of many “new uses” that the pharmaceutical industry will “discover” in order to utilize antipsychotic drugs to treat major diseases.
With the support of the Obama administration, soon we may all be on some kind of psychotropic drug.
Susanne Posel is the Chief Editor of Occupy Corporatism .